ARTV

Artiva Biotherapeutics

ARTV

Market cap $103M

4.29 USD

+0.11

2.63%

At close Updated Dec 31, 4:00 PM EST

Pre-market

After hours

4.16

-0.13

3.03%

1 day

2.63%

5 days

-0.23%

1 month

23.63%

3 months

49.48%

6 months

184.11%

Year to date

-56.97%

1 year

-57.44%

5 years

-64.25%

10 years

-64.25%

About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Employees: 106

Healthcare Biotechnology